Dynavax Technologies Corporation - Company & Market Research Reports

Dynavax is a clinical-stage biopharmaceutical company with multiple product candidates in development for the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. The company’s lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine; and AZD1419, which is in Phase II clinical trial for the treatment of asthma. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

From
From
From
From
From
Melanoma - Pipeline Review, H1 2018 - Product Thumbnail Image

Melanoma - Pipeline Review, H1 2018

  • Drug Pipelines
  • 2011 Pages
From
From
From
From
From
From
From
Anthrax - Pipeline Review, H2 2018 - Product Thumbnail Image

Anthrax - Pipeline Review, H2 2018

  • Drug Pipelines
  • 106 Pages
From
Loading Indicator
adroll